Every April 11, the world rallies for World Parkinson’s Day, honouring Dr James Parkinson, who first described “shaking palsy” in 1817. Today, his name fuels a global movement against a progressive neurological condition that steals movement and cognition.
But in 2026, it’s not only just about awareness. It’s about urgency.
Parkinson’s isn’t a distant, rare condition anymore. It impacts millions in ways healthcare systems are still struggling to keep up with.
This year’s theme, “Bridge the Care Gap,” makes that reality impossible to ignore. It’s a call to fix what’s broken: delayed diagnoses, limited specialist access, and fragmented care.
And increasingly, that fix is coming from healthtech.
The scale of the challenge
Parkinson’s (PD) is now the second-most common neurodegenerative disease worldwide, and it’s accelerating faster than any other neurological disorder.
- Global prevalence: Over 10 million people are living with Parkinson’s worldwide.
- Rising incidence: In the U.S. alone, nearly 90,000 people are diagnosed each year, a 50% increase from previous estimates.
- Demographics: Men are 1.5 times more likely to have Parkinson’s than women. While most are diagnosed after 60, ~4% are diagnosed before the age of 50.
- Economic impact: The combined direct and indirect cost of Parkinson’s (including treatment and lost income) hit ~$82.2 billion in 2024.
Health and bio tech innovators redefining Parkinson’s Care
A new wave of innovators are utilising AI, wearables, and regenerative medicine to tackle the disease. They are shifting Parkinson’s from something that’s managed occasionally into something that’s continuously understood.
1. Charco Neurotech
Founders: Lucy Jung
Year: 2019 | Location: Cambridge, UK
Charco developed the CUE1, a non-invasive wearable device. It uses high-frequency vibration (cueing) and focused stimulation to help Parkinson’s patients overcome “freezing of gait” and improve motor smoothness.
2. NeuroRPM
Founders: Atila Omer, Alexander Ksendzovsky, Jonathan Pomeraniec
Year: 2017 | Location: Washington, D.C., USA
NeuroRPM is a digital health platform that uses an AI-powered Apple Watch app to monitor Parkinson’s symptoms continuously. It tracks tremors, dyskinesia, and gait to provide clinicians with “clinical-grade” data for medication adjustments.
3. Emerald Innovations
Founders: Dina Katabi, Rumen Hristov
Year: 2018 | Location: Cambridge, USA
Emerald uses a wall-mounted sensor that utilises low-power radio signals (similar to Wi-Fi) to track a patient’s movement, breathing, and sleep at home without any wearables. Its AI can detect subtle changes in gait speed and nocturnal movements to monitor Parkinson’s progression.
4. Aspen Neuroscience
Founders: Dr. Jeanne Loring, Andrès Bratt-Leal
Year: 2018 | Location: San Diego, CA
A biotech leader developing personalised autologous cell therapies to treat Parkinson’s disease. They use a patient’s own skin cells to create induced pluripotent stem cells (iPSCs), which are then turned into dopamine-releasing neurons to replace those lost to the disease.
5. Koneksa Health
Founders: Chris Benko, Robert Ellis
Year: 2013 | Location: New York, USA
Koneksa focuses on digital biomarkers. They develop software that uses smartphone and wearable sensors to objectively measure motor function and speech, allowing pharma companies to measure disease progression and treatment impact more precisely. It helps in testing the efficacy of new Parkinson’s drugs during clinical trials.
6. GaitQ
Founders: Dr Dongli Li, Dr James Cantley and Dr André Hallack
Year: 2019 | Location: Oxford, UK
An Oxford University spin-out, GaitQ, has developed a discreet, wearable device that sits below the knee. It provides haptic (vibratory) rhythms to provide a “pace” for the user, specifically targeting the prevention of gait freezing, a common symptom in Parkinson’s disease.
7. neuroClues
Founders: Antoine Pouppez, Pierre Daye, Pierre Pouget
Year: 2020 | Location: France
neuroClues has developed a portable, high-speed eye-tracking headset that acts as a “stethoscope for the brain.” By capturing 800 infrared images per second of a patient’s eye movements, their AI identifies oculomotor biomarkers that can detect Parkinson’s and differentiate it from other neurological disorders years before visible tremors appear.
8. Neuropacs
Founders: Angelos Barmpoutis, David Vaillancourt
Year: 2021 | Location: New York, USA
Neuropacs provides a first-in-class AI-based MRI diagnostic aid. Their software analyzes standard hospital MRI scans to provide a “Parkinsonian index,” helping clinicians differentiate between Parkinson’s Disease and other similar-looking syndromes (like Multiple System Atrophy) with high statistical certainty.
New frontiers in Parkinson’s research (2025-2026)
The landscape of Parkinson’s research is shifting from managing symptoms to disease modification to actually slowing the progression of the disease.
- Diabetes Drugs for Neuroprotection: In 2024 and 2025, results from Phase 2 and Phase 3 trials of GLP-1 agonists (like Lixisenatide and Exenatide) showed significant promise. These drugs appear to reduce brain inflammation and slow the decline of motor symptoms, which can be helpful for people with Parkinson’s.
- The “Blood Test” for Parkinson’s: Researchers have made breakthroughs in identifying RNA signals in the blood that appear years before motor symptoms like tremors begin. This could allow for “pre-motor” diagnosis and earlier intervention.
- Focused Ultrasound Expansion: The FDA recently expanded approvals for MRI-guided focused ultrasound. This non-invasive procedure uses sound waves to create a tiny lesion in specific brain areas to stop severe tremors without the need for traditional “open” brain surgery (Deep Brain Stimulation).
Wrapping up
For years, Parkinson’s care has been defined by limitations: late diagnosis, trial-and-error treatments, and fragmented monitoring.
That’s changing fast.
A cure is still the goal. But today’s breakthroughs offer something just as powerful: control. Patients track their own symptoms. Clinicians see disease progression in real time.
Parkinson’s is no longer a mystery; it’s a manageable condition.
-By Alkama Sohail and the AHT Team
